Welcome to our dedicated page for AVITA Medical SEC filings (Ticker: RCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AVITA Medical's SEC filings document its therapeutic acute wound-care business, RECELL-related commercial activity, operating results, capital structure, and corporate governance. Form 8-K reports include quarterly and annual financial results, material definitive agreements, credit-facility amendments and refinancing activity, leadership appointments, and board-structure changes.
Proxy materials describe annual meeting matters such as director elections, auditor ratification, non-executive director compensation, equity-award approvals, and governance requirements tied to the company's U.S. listing and ASX-related matters. The filings also provide formal disclosure around debt obligations, subsidiary guarantees, shareholder voting items, executive compensation arrangements, and risk areas affecting AVITA Medical's wound-care operations.
AVITA Medical, Inc. President and CEO Vance Cary Guy acquired 5,000 shares of common stock through the company’s Employee Share Purchase Plan. The shares were purchased at $3.0515 per share, equal to 85% of the closing price on December 1, 2025, for the ESPP period that ran through May 31, 2026.
After this transaction, he holds 40,771 shares directly, a figure that includes unvested restricted stock units. The acquisition is classified as a grant or award and was exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating a compensation-related, routine purchase rather than an open-market trade.
AVITA Medical, Inc. CFO David D. O'Toole reported an open-market purchase of 2,000 shares of common stock at a price of $4.26 per share. Following this transaction, he directly holds 145,927 shares, which the disclosure states include unvested restricted stock units.
AVITA Medical, Inc. CFO David D. O'Toole reported an open-market purchase of common stock. He bought 2,000 shares at $4.24 per share, increasing his direct holdings to 143,927 shares. The reported total includes unvested restricted stock units, indicating both vested and unvested equity exposure.
AVITA Medical, Inc. reported first-quarter 2026 revenue of $19.3 million, up modestly from $18.5 million a year earlier, driven mainly by increased contributions from Cohealyx and RECELL GO alongside stable RECELL sales.
The company posted a net loss of $10.6 million, an improvement from a $13.9 million loss in the prior-year quarter, as operating expenses declined across sales and marketing, general and administrative, and research and development. Cash, cash equivalents, and marketable securities totaled $14.3 million as of March 31, 2026, while operating activities used $10.1 million of cash in the quarter.
AVITA refinanced its prior debt with a new five-year senior secured credit facility from Perceptive Advisors, drawing $50.0 million and receiving about $6.0 million in net proceeds after repayment of the previous credit agreement and fees. The fair value of the loan facility was $46.1 million at quarter-end, and the company reported a stockholders’ deficit of $23.2 million with an accumulated deficit of $419.0 million.
Management concluded there is “substantial doubt” about AVITA’s ability to continue as a going concern over the next twelve months due to recurring losses, negative operating cash flows, and debt repayment obligations. As a result, the long-term portion of the credit facility is classified as a current liability. The company is evaluating options such as accessing an additional $10.0 million under the facility, subject to net revenue requirements, or raising equity financing.
After quarter-end, AVITA entered a ten-year agreement with BARDA with a total potential value of up to $25.5 million, including about $3.97 million in expected access and readiness fees over the term and additional procurement options. The Board also confirmed Cary Vance as President and Chief Executive Officer and appointed Jan Stern Reed as Chair of the Board.
AVITA Medical reported first quarter 2026 revenue of approximately $19.3 million, up 4% year-over-year and about 10% sequentially, driven by Cohealyx and improved RECELL utilization as reimbursement normalizes. Gross profit margin was 81.7%, while operating expenses fell 11% to $24.5 million following cost optimization initiatives.
The company recorded a net loss of $10.6 million, or $0.35 per share, improving from a $13.9 million loss, or $0.53 per share, a year earlier. AVITA ended the quarter with $14.3 million in cash and marketable securities and net cash use of about $9.9 million, which management expects to decrease significantly in the second quarter.
The company reaffirmed full-year 2026 revenue guidance of $80 million to $85 million, implying growth of roughly 12% to 19% over 2025. AVITA also highlighted a 10-year BARDA agreement valued at up to $25.5 million, positive interim Cohealyx I clinical data, and new RECELL GO clearance in Australia and New Zealand.
AVITA Medical, Inc. appointed longtime healthcare executive Cary Vance as President and Chief Executive Officer, effective April 30, 2026, after serving as Interim CEO since October 2025. He remains on the Board as an executive director, while Jan Stern Reed has been elected Chair of the Board.
Under a new employment agreement, Mr. Vance receives a base salary of $702,000, an annual bonus target of 80% of salary, and equity awards with cash values of $2,529,000 and $825,000, subject to shareholder approval at the 2027 Annual Meeting. The equity vests over three years in equal annual installments.
If the company terminates him without cause or he resigns for good reason, Mr. Vance is eligible for severance equal to a prorated annual bonus, 18 months of base salary, and 18 months of COBRA premium reimbursement, conditioned on signing a release. The company also confirmed these governance changes in an accompanying press release.
AVITA Medical, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026. Investors will elect seven directors, ratify Grant Thornton LLP as auditor for 2026, and increase the non-executive director cash fee pool from US$750,000 to US$900,000.
Stockholders are also asked to approve multiple grants of restricted stock units and options to non-executive directors, advisory votes on executive pay and its frequency, issuance of warrants covering up to 650,000 shares to Perceptive Credit Holdings V, LP, and authority to issue additional equity securities up to 10% of issued capital under ASX rules.
AVITA Medical, Inc. filed a shelf registration statement to offer up to $200,000,000 of common stock, preferred stock, warrants and units under a Form S-3 shelf prospectus dated March 31, 2026. The prospectus states that specific terms for each offering will be set forth in a prospectus supplement. The company's common stock trades on Nasdaq under the symbol RCEL; the prospectus notes a Nasdaq closing price of $3.63 per share as of March 30, 2026. The prospectus says proceeds are expected to be used for general corporate purposes, including capital expenditures and working capital, with precise uses to be specified in future prospectus supplements.
AVITA Medical, Inc. director Woody Joseph Fralin filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director of the company and reports no buy, sell, acquire, or dispose transactions in AVITA Medical, Inc. securities.
AVITA Medical, Inc. Chief Financial Officer David D. O'Toole reported an open-market purchase of 3,000 shares of common stock on February 19, 2026 at $4.15 per share. Following this buy, his directly held stake increased to 140,127 shares, which includes unvested restricted stock units.